Specialty Generics Market
Specialty Generics Market Forecasts to 2028 - Global Analysis By Type (Oral Drugs, Injectables, Topical, Parenteral and Other Types), By Application (Hepatitis C, Multiple Sclerosis, Inflammatory Conditions, Oncology, Cardiovascular, Infectious Diseases, Autoimmune Diseases and Other Applications), By End User and By Geography
Years Covered |
2020-2028 |
Estimated Year Value (2022) |
US $69.9 BN |
Projected Year Value (2028) |
US $176.6 BN |
CAGR (2022 - 2028) |
16.7% |
Regions Covered |
North America, Europe, Asia Pacific, South America, and Middle East & Africa |
Countries Covered |
US, Canada, Mexico, Germany, UK, Italy, France, Spain, Japan, China, India, Australia, New Zealand, South Korea, Rest of Asia Pacific, South America, Argentina, Brazil, Chile, Middle East & Africa, Saudi Arabia, UAE, Qatar, and South Africa |
Largest Market |
North America |
Highest Growing Market |
Asia Pacific |
According to Stratistics MRC, the Global Specialty Generics Market is accounted for $69.9 billion in 2022 and is expected to reach $176.6 billion by 2028 growing at a CAGR of 16.7% during the forecast period. Once a specialty drug's patent expires, generic versions of it are referred to as specialty generics. Complex, chronic diseases like cancer, multiple sclerosis, and rheumatoid arthritis may all be treated with these medications. Specialty generics are less expensive than branded equivalents because they have lower development and marketing expenses.
According to the World Health Organization (WHO), the geriatric population increased from 1 billion in 2020 to 1.4 billion in 2021. By 2030, one in six people in the world will be aged 60 years and above.
Market Dynamics:
Driver:
Increasing cases of chronic diseases to fuel the demand for specialty generics
Globally, there have been more incidences of numerous life-threatening illnesses, such as cancer, multiple sclerosis (MS), and HIV, and it is projected that this will lead to a rise in the use of specialty medications. For instance, according to data from the Global RA Network published in 2021, there are already 350 million individuals living with arthritis worldwide, and this number is likely to rise over the next few years. Additionally, according to data released by Globocan in 2020, 9.7% of the world's population, or Europe, represented 19.6% of cancer deaths and 22.8% of all cancer diagnoses.
Restraint:
High capital cost and complex manufacturing requirements
Due to the sophisticated manufacturing needs, greater capital expenditures, and generally lower quantities as a result of a smaller patient population, specialist generics have a more competitive market than regular generics. Specialty generic drugs typically require prior authorization to be ordered, specific handling, administration, and monitoring. These elements are further hindering the market growth.
Opportunity:
Patent expiration of specialty drugs
As payers and patients seek methods to save healthcare costs, demand for specialty generics is expanding globally. To ensure that patients who require advanced generic medicines have access to them, a number of well-known market participants are concentrating on the release of generic versions of medications. For instance, Teva Pharmaceuticals, Inc. introduced Revlimid (capsules containing lenalidomide) in the United States in March 2022. In order to treat multiple myeloma in adults, the first generic version of Revlimid was introduced in strengths of 5mg, 10mg, 15mg, and 25mg.
Threat:
Lack of awareness and low profitability
High complexity of specialist generic medicines, low profitability, and brand recognition and loyalty are important issues that, to some extent, restrict market expansion. People are bearing the burden of rising healthcare costs as a result of the general public's lack of knowledge about the availability of generic medications at pharmacies, which forces them to spend more on branded medications. During the projected period, these factors are anticipated to limit the market's growth.
Covid-19 Impact:
The COVID-19 pandemic's impact on the market caused the industry to grow more slowly as a result of the suspension of various research trials and studies following the big virus epidemic, lockdown limitations in industrial facilities, and a lack of qualified employees. Additionally, a number of pharmaceutical firms witnessed a reduction in their net revenues in 2020 as a result of COVID-19. Instead, due to widespread vaccinations, a relaxation of lockdown restrictions, and a rise in the need for specialist medications to treat chronic ailments, the market recovered in 2021 as compared to 2020.
The oral drugs segment is expected to be the largest during the forecast period
Oral Drugs segment is expected to have dominant share throughout the projection period. The quickest, simplest, and safest method of administration for generic medications is oral. As a result of their ease of use for frequent and sustained usage, self-administration, and lack of pain, they are the most often used and manufactured form of pharmaceuticals. The product launches credited with the segment's supremacy in the market attract the attention of market participants. For instance, Par Pharmaceutical, Inc. (Par), a subsidiary of Endo International plc, was granted FDA approval in January 2022 to market the country's first generic version of Merz's CUVPOSA (glycopyrrolate).
The oncology segment is expected to have the highest CAGR during the forecast period
Oncology segment accounted for lucrative growth over the forecasted period, because there are more generic cancer medications available and there is a greater demand for cancer treatment solutions that are effective. For instance, Sun Pharmaceutical Industries Ltd. introduced the generic version of Palbociclib, a breast cancer treatment from Pfizer, in India in January 2023. These factors are anticipated to boost segment growth due to the adoption of a Western lifestyle, excessive alcohol and tobacco use, poor dietary choices, and physical inactivity.
Region with largest share:
North America is expected to have the largest share during the domination period, due to the existence of regulatory policies that favor the approval of innovative products. The American FDA has launched a number of initiatives aimed at streamlining the entire approval procedure. Thus, the Hatch-Waxman Act's Generic Drug User Free Amendments (GDUFA) were introduced by the U.S. FDA to accelerate the distribution of affordable, safe, and effective generic medications to the general population. Therefore, the major producers continually work to commercialize specialty generic medicines on the market.
Region with highest CAGR:
Asia Pacific region is anticipated to witness rapid growth throughout the extrapolated period, due to the expansion of biopharmaceutical companies in China and India, which is anticipated to drive the market in this region. Additionally, the region is expanding as a result of the favorable regulatory regulations governing the approval and introduction of new generic drugs there. However, pharmaceutical companies are continually working to promote specialty medications in the region. The market in the Asia-Pacific area has grown as a result of these factors.
Key players in the market
Some of the key players in Specialty Generics market include Akorn, Inc., Amneal Pharmaceuticals LLC, Bausch Health Companies Inc, Dr. Reddy’s Laboratories, Ltd., Endo International plc., Endo Pharmaceuticals Inc., Hikma Pharmaceuticals PLC, Lupin, Mallinckrodt, Mylan N.V., Novartis AG, Pfizer, Inc., Sandoz International GmbH, Sun Pharmaceutical Industries, Ltd., Teva Pharmaceuticals USA, Inc. and Viatris Inc..
Key Developments:
In June 2022, Amneal Pharmaceuticals Inc., launched LYVISPAH (baclofen) a specialty product approved by U.S. FDA for the indication of multiple sclerosis and other spinal cord disorders.
In March 2022, Viatris Inc. announced receipt of the first FDA approval for a generic version of Symbicort Inhalation Aerosol, Breyna (Budesonide and Formoterol Fumarate Dihydrate Inhalation Aerosol), in partnership with Kindeva Drug Delivery L.P. for the treatment of chronic obstructive pulmonary disease (COPD).
In January 2022, Lupin Limited partnered with the Chinese Shenzhen Foncoo Pharmaceutical Co., Ltd. The partnership aimed to sell complex generics and specialty medicines to China.
Types Covered:
• Oral Drugs
• Injectables
• Topical
• Parenteral
• Other Types
Applications Covered:
• Hepatitis C
• Multiple Sclerosis
• Inflammatory Conditions
• Oncology
• Cardiovascular
• Infectious Diseases
• Autoimmune Diseases
• Other Applications
End Users Covered:
• Hospital Pharmacy
• Retail Pharmacy
• Specialty Pharmacy
• Online Pharmacies
• Other End Users
Regions Covered:
• North America
o US
o Canada
o Mexico
• Europe
o Germany
o UK
o Italy
o France
o Spain
o Rest of Europe
• Asia Pacific
o Japan
o China
o India
o Australia
o New Zealand
o South Korea
o Rest of Asia Pacific
• South America
o Argentina
o Brazil
o Chile
o Rest of South America
• Middle East & Africa
o Saudi Arabia
o UAE
o Qatar
o South Africa
o Rest of Middle East & Africa
What our report offers:
- Market share assessments for the regional and country-level segments
- Strategic recommendations for the new entrants
- Covers Market data for the years 2020, 2021, 2022, 2025, and 2028
- Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
- Strategic recommendations in key business segments based on the market estimations
- Competitive landscaping mapping the key common trends
- Company profiling with detailed strategies, financials, and recent developments
- Supply chain trends mapping the latest technological advancements
Free Customization Offerings:
All the customers of this report will be entitled to receive one of the following free customization options:
• Company Profiling
o Comprehensive profiling of additional market players (up to 3)
o SWOT Analysis of key players (up to 3)
• Regional Segmentation
o Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
• Competitive Benchmarking
Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances
Table of Contents
1 Executive Summary
2 Preface
2.1 Abstract
2.2 Stake Holders
2.3 Research Scope
2.4 Research Methodology
2.4.1 Data Mining
2.4.2 Data Analysis
2.4.3 Data Validation
2.4.4 Research Approach
2.5 Research Sources
2.5.1 Primary Research Sources
2.5.2 Secondary Research Sources
2.5.3 Assumptions
3 Market Trend Analysis
3.1 Introduction
3.2 Drivers
3.3 Restraints
3.4 Opportunities
3.5 Threats
3.6 Application Analysis
3.7 End User Analysis
3.8 Emerging Markets
3.9 Impact of Covid-19
4 Porters Five Force Analysis
4.1 Bargaining power of suppliers
4.2 Bargaining power of buyers
4.3 Threat of substitutes
4.4 Threat of new entrants
4.5 Competitive rivalry
5 Global Specialty Generics Market, By Type
5.1 Introduction
5.2 Oral Drugs
5.3 Injectables
5.4 Topical
5.5 Parenteral
5.6 Other Types
6 Global Specialty Generics Market, By Application
6.1 Introduction
6.2 Hepatitis C
6.3 Multiple Sclerosis
6.4 Inflammatory Conditions
6.5 Oncology
6.6 Cardiovascular
6.7 Infectious Diseases
6.8 Autoimmune Diseases
6.9 Other Applications
7 Global Specialty Generics Market, By End User
7.1 Introduction
7.2 Hospital Pharmacy
7.3 Retail Pharmacy
7.4 Specialty Pharmacy
7.5 Online Pharmacies
7.6 Other End Users
8 Global Specialty Generics Market, By Geography
8.1 Introduction
8.2 North America
8.2.1 US
8.2.2 Canada
8.2.3 Mexico
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 Italy
8.3.4 France
8.3.5 Spain
8.3.6 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 New Zealand
8.4.6 South Korea
8.4.7 Rest of Asia Pacific
8.5 South America
8.5.1 Argentina
8.5.2 Brazil
8.5.3 Chile
8.5.4 Rest of South America
8.6 Middle East & Africa
8.6.1 Saudi Arabia
8.6.2 UAE
8.6.3 Qatar
8.6.4 South Africa
8.6.5 Rest of Middle East & Africa
9 Key Developments
9.1 Agreements, Partnerships, Collaborations and Joint Ventures
9.2 Acquisitions & Mergers
9.3 New Product Launch
9.4 Expansions
9.5 Other Key Strategies
10 Company Profiling
10.1 Akorn, Inc.
10.2 Amneal Pharmaceuticals LLC
10.3 Bausch Health Companies Inc
10.4 Dr. Reddy’s Laboratories, Ltd.
10.5 Endo International plc.
10.6 Endo Pharmaceuticals Inc.
10.7 Hikma Pharmaceuticals PLC
10.8 Lupin
10.9 Mallinckrodt
10.10 Mylan N.V.
10.11 Novartis AG
10.12 Pfizer, Inc.
10.13 Sandoz International GmbH
10.14 Sun Pharmaceutical Industries, Ltd.
10.15 Teva Pharmaceuticals USA, Inc.
10.16 Viatris Inc.
List of Tables
1 Global Specialty Generics Market Outlook, By Region (2020-2028) ($MN)
2 Global Specialty Generics Market Outlook, By Type (2020-2028) ($MN)
3 Global Specialty Generics Market Outlook, By Oral Drugs (2020-2028) ($MN)
4 Global Specialty Generics Market Outlook, By Injectables (2020-2028) ($MN)
5 Global Specialty Generics Market Outlook, By Topical (2020-2028) ($MN)
6 Global Specialty Generics Market Outlook, By Parenteral (2020-2028) ($MN)
7 Global Specialty Generics Market Outlook, By Other Types (2020-2028) ($MN)
8 Global Specialty Generics Market Outlook, By Application (2020-2028) ($MN)
9 Global Specialty Generics Market Outlook, By Hepatitis C (2020-2028) ($MN)
10 Global Specialty Generics Market Outlook, By Multiple Sclerosis (2020-2028) ($MN)
11 Global Specialty Generics Market Outlook, By Inflammatory Conditions (2020-2028) ($MN)
12 Global Specialty Generics Market Outlook, By Oncology (2020-2028) ($MN)
13 Global Specialty Generics Market Outlook, By Cardiovascular (2020-2028) ($MN)
14 Global Specialty Generics Market Outlook, By Infectious Diseases (2020-2028) ($MN)
15 Global Specialty Generics Market Outlook, By Autoimmune Diseases (2020-2028) ($MN)
16 Global Specialty Generics Market Outlook, By Other Applications (2020-2028) ($MN)
17 Global Specialty Generics Market Outlook, By End User (2020-2028) ($MN)
18 Global Specialty Generics Market Outlook, By Hospital Pharmacy (2020-2028) ($MN)
19 Global Specialty Generics Market Outlook, By Retail Pharmacy (2020-2028) ($MN)
20 Global Specialty Generics Market Outlook, By Specialty Pharmacy (2020-2028) ($MN)
21 Global Specialty Generics Market Outlook, By Online Pharmacies (2020-2028) ($MN)
22 Global Specialty Generics Market Outlook, By Other End Users (2020-2028) ($MN)
23 North America Specialty Generics Market Outlook, By Country (2020-2028) ($MN)
24 North America Specialty Generics Market Outlook, By Type (2020-2028) ($MN)
25 North America Specialty Generics Market Outlook, By Oral Drugs (2020-2028) ($MN)
26 North America Specialty Generics Market Outlook, By Injectables (2020-2028) ($MN)
27 North America Specialty Generics Market Outlook, By Topical (2020-2028) ($MN)
28 North America Specialty Generics Market Outlook, By Parenteral (2020-2028) ($MN)
29 North America Specialty Generics Market Outlook, By Other Types (2020-2028) ($MN)
30 North America Specialty Generics Market Outlook, By Application (2020-2028) ($MN)
31 North America Specialty Generics Market Outlook, By Hepatitis C (2020-2028) ($MN)
32 North America Specialty Generics Market Outlook, By Multiple Sclerosis (2020-2028) ($MN)
33 North America Specialty Generics Market Outlook, By Inflammatory Conditions (2020-2028) ($MN)
34 North America Specialty Generics Market Outlook, By Oncology (2020-2028) ($MN)
35 North America Specialty Generics Market Outlook, By Cardiovascular (2020-2028) ($MN)
36 North America Specialty Generics Market Outlook, By Infectious Diseases (2020-2028) ($MN)
37 North America Specialty Generics Market Outlook, By Autoimmune Diseases (2020-2028) ($MN)
38 North America Specialty Generics Market Outlook, By Other Applications (2020-2028) ($MN)
39 North America Specialty Generics Market Outlook, By End User (2020-2028) ($MN)
40 North America Specialty Generics Market Outlook, By Hospital Pharmacy (2020-2028) ($MN)
41 North America Specialty Generics Market Outlook, By Retail Pharmacy (2020-2028) ($MN)
42 North America Specialty Generics Market Outlook, By Specialty Pharmacy (2020-2028) ($MN)
43 North America Specialty Generics Market Outlook, By Online Pharmacies (2020-2028) ($MN)
44 North America Specialty Generics Market Outlook, By Other End Users (2020-2028) ($MN)
45 Europe Specialty Generics Market Outlook, By Country (2020-2028) ($MN)
46 Europe Specialty Generics Market Outlook, By Type (2020-2028) ($MN)
47 Europe Specialty Generics Market Outlook, By Oral Drugs (2020-2028) ($MN)
48 Europe Specialty Generics Market Outlook, By Injectables (2020-2028) ($MN)
49 Europe Specialty Generics Market Outlook, By Topical (2020-2028) ($MN)
50 Europe Specialty Generics Market Outlook, By Parenteral (2020-2028) ($MN)
51 Europe Specialty Generics Market Outlook, By Other Types (2020-2028) ($MN)
52 Europe Specialty Generics Market Outlook, By Application (2020-2028) ($MN)
53 Europe Specialty Generics Market Outlook, By Hepatitis C (2020-2028) ($MN)
54 Europe Specialty Generics Market Outlook, By Multiple Sclerosis (2020-2028) ($MN)
55 Europe Specialty Generics Market Outlook, By Inflammatory Conditions (2020-2028) ($MN)
56 Europe Specialty Generics Market Outlook, By Oncology (2020-2028) ($MN)
57 Europe Specialty Generics Market Outlook, By Cardiovascular (2020-2028) ($MN)
58 Europe Specialty Generics Market Outlook, By Infectious Diseases (2020-2028) ($MN)
59 Europe Specialty Generics Market Outlook, By Autoimmune Diseases (2020-2028) ($MN)
60 Europe Specialty Generics Market Outlook, By Other Applications (2020-2028) ($MN)
61 Europe Specialty Generics Market Outlook, By End User (2020-2028) ($MN)
62 Europe Specialty Generics Market Outlook, By Hospital Pharmacy (2020-2028) ($MN)
63 Europe Specialty Generics Market Outlook, By Retail Pharmacy (2020-2028) ($MN)
64 Europe Specialty Generics Market Outlook, By Specialty Pharmacy (2020-2028) ($MN)
65 Europe Specialty Generics Market Outlook, By Online Pharmacies (2020-2028) ($MN)
66 Europe Specialty Generics Market Outlook, By Other End Users (2020-2028) ($MN)
67 Asia Pacific Specialty Generics Market Outlook, By Country (2020-2028) ($MN)
68 Asia Pacific Specialty Generics Market Outlook, By Type (2020-2028) ($MN)
69 Asia Pacific Specialty Generics Market Outlook, By Oral Drugs (2020-2028) ($MN)
70 Asia Pacific Specialty Generics Market Outlook, By Injectables (2020-2028) ($MN)
71 Asia Pacific Specialty Generics Market Outlook, By Topical (2020-2028) ($MN)
72 Asia Pacific Specialty Generics Market Outlook, By Parenteral (2020-2028) ($MN)
73 Asia Pacific Specialty Generics Market Outlook, By Other Types (2020-2028) ($MN)
74 Asia Pacific Specialty Generics Market Outlook, By Application (2020-2028) ($MN)
75 Asia Pacific Specialty Generics Market Outlook, By Hepatitis C (2020-2028) ($MN)
76 Asia Pacific Specialty Generics Market Outlook, By Multiple Sclerosis (2020-2028) ($MN)
77 Asia Pacific Specialty Generics Market Outlook, By Inflammatory Conditions (2020-2028) ($MN)
78 Asia Pacific Specialty Generics Market Outlook, By Oncology (2020-2028) ($MN)
79 Asia Pacific Specialty Generics Market Outlook, By Cardiovascular (2020-2028) ($MN)
80 Asia Pacific Specialty Generics Market Outlook, By Infectious Diseases (2020-2028) ($MN)
81 Asia Pacific Specialty Generics Market Outlook, By Autoimmune Diseases (2020-2028) ($MN)
82 Asia Pacific Specialty Generics Market Outlook, By Other Applications (2020-2028) ($MN)
83 Asia Pacific Specialty Generics Market Outlook, By End User (2020-2028) ($MN)
84 Asia Pacific Specialty Generics Market Outlook, By Hospital Pharmacy (2020-2028) ($MN)
85 Asia Pacific Specialty Generics Market Outlook, By Retail Pharmacy (2020-2028) ($MN)
86 Asia Pacific Specialty Generics Market Outlook, By Specialty Pharmacy (2020-2028) ($MN)
87 Asia Pacific Specialty Generics Market Outlook, By Online Pharmacies (2020-2028) ($MN)
88 Asia Pacific Specialty Generics Market Outlook, By Other End Users (2020-2028) ($MN)
89 South America Specialty Generics Market Outlook, By Country (2020-2028) ($MN)
90 South America Specialty Generics Market Outlook, By Type (2020-2028) ($MN)
91 South America Specialty Generics Market Outlook, By Oral Drugs (2020-2028) ($MN)
92 South America Specialty Generics Market Outlook, By Injectables (2020-2028) ($MN)
93 South America Specialty Generics Market Outlook, By Topical (2020-2028) ($MN)
94 South America Specialty Generics Market Outlook, By Parenteral (2020-2028) ($MN)
95 South America Specialty Generics Market Outlook, By Other Types (2020-2028) ($MN)
96 South America Specialty Generics Market Outlook, By Application (2020-2028) ($MN)
97 South America Specialty Generics Market Outlook, By Hepatitis C (2020-2028) ($MN)
98 South America Specialty Generics Market Outlook, By Multiple Sclerosis (2020-2028) ($MN)
99 South America Specialty Generics Market Outlook, By Inflammatory Conditions (2020-2028) ($MN)
100 South America Specialty Generics Market Outlook, By Oncology (2020-2028) ($MN)
101 South America Specialty Generics Market Outlook, By Cardiovascular (2020-2028) ($MN)
102 South America Specialty Generics Market Outlook, By Infectious Diseases (2020-2028) ($MN)
103 South America Specialty Generics Market Outlook, By Autoimmune Diseases (2020-2028) ($MN)
104 South America Specialty Generics Market Outlook, By Other Applications (2020-2028) ($MN)
105 South America Specialty Generics Market Outlook, By End User (2020-2028) ($MN)
106 South America Specialty Generics Market Outlook, By Hospital Pharmacy (2020-2028) ($MN)
107 South America Specialty Generics Market Outlook, By Retail Pharmacy (2020-2028) ($MN)
108 South America Specialty Generics Market Outlook, By Specialty Pharmacy (2020-2028) ($MN)
109 South America Specialty Generics Market Outlook, By Online Pharmacies (2020-2028) ($MN)
110 South America Specialty Generics Market Outlook, By Other End Users (2020-2028) ($MN)
111 Middle East & Africa Specialty Generics Market Outlook, By Country (2020-2028) ($MN)
112 Middle East & Africa Specialty Generics Market Outlook, By Type (2020-2028) ($MN)
113 Middle East & Africa Specialty Generics Market Outlook, By Oral Drugs (2020-2028) ($MN)
114 Middle East & Africa Specialty Generics Market Outlook, By Injectables (2020-2028) ($MN)
115 Middle East & Africa Specialty Generics Market Outlook, By Topical (2020-2028) ($MN)
116 Middle East & Africa Specialty Generics Market Outlook, By Parenteral (2020-2028) ($MN)
117 Middle East & Africa Specialty Generics Market Outlook, By Other Types (2020-2028) ($MN)
118 Middle East & Africa Specialty Generics Market Outlook, By Application (2020-2028) ($MN)
119 Middle East & Africa Specialty Generics Market Outlook, By Hepatitis C (2020-2028) ($MN)
120 Middle East & Africa Specialty Generics Market Outlook, By Multiple Sclerosis (2020-2028) ($MN)
121 Middle East & Africa Specialty Generics Market Outlook, By Inflammatory Conditions (2020-2028) ($MN)
122 Middle East & Africa Specialty Generics Market Outlook, By Oncology (2020-2028) ($MN)
123 Middle East & Africa Specialty Generics Market Outlook, By Cardiovascular (2020-2028) ($MN)
124 Middle East & Africa Specialty Generics Market Outlook, By Infectious Diseases (2020-2028) ($MN)
125 Middle East & Africa Specialty Generics Market Outlook, By Autoimmune Diseases (2020-2028) ($MN)
126 Middle East & Africa Specialty Generics Market Outlook, By Other Applications (2020-2028) ($MN)
127 Middle East & Africa Specialty Generics Market Outlook, By End User (2020-2028) ($MN)
128 Middle East & Africa Specialty Generics Market Outlook, By Hospital Pharmacy (2020-2028) ($MN)
129 Middle East & Africa Specialty Generics Market Outlook, By Retail Pharmacy (2020-2028) ($MN)
130 Middle East & Africa Specialty Generics Market Outlook, By Specialty Pharmacy (2020-2028) ($MN)
131 Middle East & Africa Specialty Generics Market Outlook, By Online Pharmacies (2020-2028) ($MN)
132 Middle East & Africa Specialty Generics Market Outlook, By Other End Users (2020-2028) ($MN)
List of Figures
RESEARCH METHODOLOGY
We at ‘Stratistics’ opt for an extensive research approach which involves data mining, data validation, and data analysis. The various research sources include in-house repository, secondary research, competitor’s sources, social media research, client internal data, and primary research.
Our team of analysts prefers the most reliable and authenticated data sources in order to perform the comprehensive literature search. With access to most of the authenticated data bases our team highly considers the best mix of information through various sources to obtain extensive and accurate analysis.
Each report takes an average time of a month and a team of 4 industry analysts. The time may vary depending on the scope and data availability of the desired market report. The various parameters used in the market assessment are standardized in order to enhance the data accuracy.
Data Mining
The data is collected from several authenticated, reliable, paid and unpaid sources and is filtered depending on the scope & objective of the research. Our reports repository acts as an added advantage in this procedure. Data gathering from the raw material suppliers, distributors and the manufacturers is performed on a regular basis, this helps in the comprehensive understanding of the products value chain. Apart from the above mentioned sources the data is also collected from the industry consultants to ensure the objective of the study is in the right direction.
Market trends such as technological advancements, regulatory affairs, market dynamics (Drivers, Restraints, Opportunities and Challenges) are obtained from scientific journals, market related national & international associations and organizations.
Data Analysis
From the data that is collected depending on the scope & objective of the research the data is subjected for the analysis. The critical steps that we follow for the data analysis include:
- Product Lifecycle Analysis
- Competitor analysis
- Risk analysis
- Porters Analysis
- PESTEL Analysis
- SWOT Analysis
The data engineering is performed by the core industry experts considering both the Marketing Mix Modeling and the Demand Forecasting. The marketing mix modeling makes use of multiple-regression techniques to predict the optimal mix of marketing variables. Regression factor is based on a number of variables and how they relate to an outcome such as sales or profits.
Data Validation
The data validation is performed by the exhaustive primary research from the expert interviews. This includes telephonic interviews, focus groups, face to face interviews, and questionnaires to validate our research from all aspects. The industry experts we approach come from the leading firms, involved in the supply chain ranging from the suppliers, distributors to the manufacturers and consumers so as to ensure an unbiased analysis.
We are in touch with more than 15,000 industry experts with the right mix of consultants, CEO's, presidents, vice presidents, managers, experts from both supply side and demand side, executives and so on.
The data validation involves the primary research from the industry experts belonging to:
- Leading Companies
- Suppliers & Distributors
- Manufacturers
- Consumers
- Industry/Strategic Consultants
Apart from the data validation the primary research also helps in performing the fill gap research, i.e. providing solutions for the unmet needs of the research which helps in enhancing the reports quality.
For more details about research methodology, kindly write to us at info@strategymrc.com
Frequently Asked Questions
In case of any queries regarding this report, you can contact the customer service by filing the “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
Yes, the samples are available for all the published reports. You can request them by filling the “Request Sample” option available in this page.
Yes, you can request a sample with your specific requirements. All the customized samples will be provided as per the requirement with the real data masked.
All our reports are available in Digital PDF format. In case if you require them in any other formats, such as PPT, Excel etc you can submit a request through “Inquiry Before Buy” form available on the right hand side. You may also contact us through email: info@strategymrc.com or phone: +1-301-202-5929
We offer a free 15% customization with every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
We have 3 different licensing options available in electronic format.
- Single User Licence: Allows one person, typically the buyer, to have access to the ordered product. The ordered product cannot be distributed to anyone else.
- 2-5 User Licence: Allows the ordered product to be shared among a maximum of 5 people within your organisation.
- Corporate License: Allows the product to be shared among all employees of your organisation regardless of their geographical location.
All our reports are typically be emailed to you as an attachment.
To order any available report you need to register on our website. The payment can be made either through CCAvenue or PayPal payments gateways which accept all international cards.
We extend our support to 6 months post sale. A post sale customization is also provided to cover your unmet needs in the report.
Request Customization
We provide a free 15% customization on every purchase. This requirement can be fulfilled for both pre and post sale. You may send your customization requirements through email at info@strategymrc.com or call us on +1-301-202-5929.
Note: This customization is absolutely free until it falls under the 15% bracket. If your requirement exceeds this a feasibility check will be performed. Post that, a quote will be provided along with the timelines.
WHY CHOOSE US ?
Assured Quality
Best in class reports with high standard of research integrity
24X7 Research Support
Continuous support to ensure the best customer experience.
Free Customization
Adding more values to your product of interest.
Safe & Secure Access
Providing a secured environment for all online transactions.
Trusted by 600+ Brands
Serving the most reputed brands across the world.